Results 71 to 80 of about 61,613 (221)

Blood-brain barrier disruption and delivery of irinotecan in a rat model using a clinical transcranial MRI-guided focused ultrasound system

Scientific Reports, 2020
We investigated controlled blood-brain barrier (BBB) disruption using a low-frequency clinical transcranial MRI-guided focused ultrasound (TcMRgFUS) device and evaluated enhanced delivery of irinotecan chemotherapy to the brain and a rat glioma model ...
Nathan McDannold, Yongzhi Zhang, Jeffrey G. Supko, Chanikarn Power, Tao Sun, Natalia Vykhodtseva, Alexandra J. Golby, David A. Reardon   +7 more
doaj   +1 more source

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum, Milli McMenamin, Tessa Khoo, John M. Edwin, Prathibha Jose, Liam A. O’Callaghan   +5 more
wiley   +1 more source

Implementation of Pharmacogenomics in Pediatric‐Focused Institutions Within the Pharmacogenomics Global Research Network

Clinical Pharmacology &Therapeutics, EarlyView.
Descriptions of how pediatric‐focused institutions implement pharmacogenomic testing are scarce, and often not differentiated from adult‐focused institutions. We aimed to provide a detailed description of how pediatric‐focused institutions across the world implemented pharmacogenomic testing in clinical practice.
Laura B. Ramsey, Chad Bousman, Rebecca Brand, Kelsey Cook, David B. Gregornik, Cyrine E. Haidar, Nancy Hakooz, Nicole Keuler, Nathan Lamb, Mohamed Nagy, Jenny Q. Nguyen, Courtney Paetznick, April Schultz, D. Max Smith, Evangelia Eirini Tsermpini, Amanda L. Elchynski   +15 more
wiley   +1 more source

The Adaptor Protein Myd88 Is a Key Signaling Molecule in the Pathogenesis of Irinotecan-Induced Intestinal Mucositis. [PDF]

PLoS ONE, 2015
Intestinal mucositis is a common side effect of irinotecan-based anticancer regimens. Mucositis causes cell damage, bacterial/endotoxin translocation and production of cytokines including IL-1 and IL-18.
Deysi V T Wong, Roberto C P Lima-Júnior, Cibele B M Carvalho, Vanessa F Borges, Carlos W S Wanderley, Amanda X C Bem, Caio A V G Leite, Maraiza A Teixeira, Gabriela L P Batista, Rangel L Silva, Thiago M Cunha, Gerly A C Brito, Paulo R C Almeida, Fernando Q Cunha, Ronaldo A Ribeiro   +14 more
doaj   +1 more source

Patient data best-fit of irinotecan PK model.

, 2020
Each subplot represents an individual patient dataset, fit to the model independently. (A) shows the fit of irinotecan plasma concentration, (B) shows that of SN38, the active metabolite of irinotecan.
Roger J. W. Hill (8363451), Francis Lévi (4784820), Pasquale F. Innominato (8363454), Annabelle Ballesta (119580)   +3 more
core   +1 more source

Prediction of novel target genes and pathways involved in irinotecan-resistant colorectal cancer. [PDF]

, 2017
Acquired drug resistance to the chemotherapeutic drug irinotecan (the active metabolite of which is SN-38) is one of the significant obstacles in the treatment of advanced colorectal cancer (CRC).
Chu, CM, Po-Li Wei, Chi-Ming Chu, Wei, PL, Precious Takondwa Makondi, Yu-Jia Chang, Makondi, PT, Chang, YJ   +7 more
core   +1 more source

Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06)

BMC Cancer
Background Immune checkpoint inhibitor (ICI) or irinotecan-based chemotherapy is frequently used after failure of second-line paclitaxel plus ramucirumab treatment for patients with locally advanced unresectable or metastatic advanced gastric cancer (AGC)
Sung Hee Lim, Keun-Wook Lee, Jae-Joon Kim, Hyeon-Su Im, In-Ho Kim, Hye Sook Han, Dong-Hoe Koo, Jang Ho Cho, Chi Hoon Maeng, Min-Young Lee, Hyo Jin Lee, Jwa Hoon Kim, Sang Gon Park, Joo Young Jung, Seong-Hoon Shin, Ki Hyang Kim, Hyeyeong Kim, So Yeon Oh, Minsu Kang, Minkyu Jung, Sun Young Rha   +20 more
doaj   +1 more source

P-glycoprotein-dependent pharmacokinetics of irinotecan and its active metabolite, SN-38 in rats: Effect of verapamil

ADMET and DMPK, 2015
We have recently demonstrated that the oral bioavailability of irinotecan (80 mg/kg) can be increased at least 7-fold by co-administration of the P-gp blocker verapamil (25 mg/kg, Oral).
Tripta Garg, Manu Jaggi, Roop K. Khar, Sushama Talegaonkar   +3 more
doaj   +1 more source

ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients

Frontiers in Pharmacology, 2020
Irinotecan is widely used in the treatment of metastatic colorectal cancer (mCRC) despite its severe toxicities. Toxicity is often associated with the UGT1A1*28/*28 genotype.
Pau Riera, Pau Riera, Pau Riera, Alícia Artigas-Baleri, Juliana Salazar, Ana Sebio, Anna C. Virgili, María Jesús Arranz, David Páez, David Páez   +9 more
doaj   +1 more source

Perioperative Rehabilitation and Initiation of Adjuvant Chemotherapy in Resected Non‐Small Cell Lung Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Adjuvant chemotherapy can improve outcomes for patients who have undergone lung cancer resection, and perioperative rehabilitation may help maintain the physical condition necessary to receive adjuvant chemotherapy. This observational cohort study investigated the impact of perioperative rehabilitation on the administration of postoperative ...
Shinkichi Takamori, Tateaki Naito, Nobuko Konishi, Tetsuya Tsuji, Ikumi Takashima, Ryotaro Ide, Masakazu Fujiwara, Atsuki Yamamoto, Yusuke Takagi, Mizue Ogi, Shinya Uematsu, Hiroshi Kitagawa, Koichi Takayama   +12 more
wiley   +1 more source